A phase Ila clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumours harboring wild -type p53 and MDM2 amplification or MDM2/CDK4 co-amplification

被引：0
|
作者：
Meric-Bernstam, F. [1 ]
Somaiah, N. [2 ]
DuBois, S. G. [3 ,4 ]
Dumbrava, E. E. Ileana [1 ]
Shapiro, G. I. [4 ]
Patel, M. R. [5 ]
Goel, S. [6 ]
Bauer, T. [7 ]
Pinchasik, D. [8 ]
Annis, A. [9 ]
Aivado, M. [10 ]
Vukovic, V. [11 ]
Saleh, M. [12 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Sarcoma Med Oncol, Houston, TX 77030 USA
[3] Dana Farber & Boston Childrens, Pediat Oncol, Boston, MA USA
[4] Dana Farber Canc Inst, Early Drug Dev Ctr, Boston, MA 02115 USA
[5] Florida Canc Specialists & Res Inst, Med Oncol, Sarasota, FL USA
[6] Montefiore Med Ctr, Med Oncol, Eastchester Albert Einstein Canc Ctr, East Campus,Med Pk, New York, NY USA
[7] Sarah Cannon Res Inst, Drug Dev, Nashville, TN USA
[8] Aileron Therapeut Inc, Clin Dev, Cambridge, MA USA
[9] Aileron Therapeut Inc, Res, Watertown, MA USA
[10] Aileron Therapeut Inc, Res & Drug Dev, Watertown, MA USA
[11] Aileron Therapeut Inc, Clin & Med, Watertown, MA USA
[12] Univ Alabama Birmingham, ONeal Comprehens Canc Ctr, Hematol Oncol, Birmingham, AL USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
475P
引用
收藏
页码：179 / +
页数：2
相关论文
共 50 条
  • [21] Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment
    Pujals, Anais
    Favre, Loetitia
    Gaulard, Philippe
    Wiels, Joelle
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2015, 5
  • [22] Prognostic value of MGMT promoter hypermethylation, TP53 mutation, MDM2, EGFR and CDK4 amplification in malignant glioma patients
    Loeser, S
    Luyken, C
    Blaschke, B
    Köhler, S
    Kreuzmann, A
    Seghrouchni, S
    Reifenberger, G
    Sabel, M
    ACTA NEUROPATHOLOGICA, 2005, 110 (03) : 332 - 332
  • [23] Defective p53 post-translational modification required for wild type p53 inactivation in malignant epithelial cells with mdm2 gene amplification
    Knights, CD
    Liu, YG
    Appella, E
    Kulesz-Martin, M
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (52) : 52890 - 52900
  • [24] In Vitro andpre-Clinical In Vivo evidence Support MDMX/MDM2 As Common Vulnerabilities across TP53 -Wild-Type T-Cell Lymphomas That Are Targetable with the α-Helical p53 Stapled Peptide Alrn-6924
    Koch, Raphael
    Christie, Amanda L.
    Yoshida, Noriaki
    Ng, Samuel Y.
    Shigemori, Kay
    Morrow, Sara N.
    Van Scoyk, Alexandria
    Horwitz, Steven M.
    Jacobsen, Eric
    Santiago, Solimar
    Ren, Jian-Guo
    Guerlavais, Vincent
    Annis, D. Allan
    Aivado, Manuel A.
    Weinstock, David M.
    BLOOD, 2017, 130
  • [25] CD133 SURVIVAL ANALYSIS IN GLIOMA PATIENTS: RELATIONSHIP WITH CDK4, EGFR, P53, MDM2, AND PTEN MOLECULES
    Ruano, Yolanda
    de Lope, Angel Rodriguez
    Perez-Magan, Elisa
    Mollejo, Manuela
    Campos-Martin, Yolanda
    Garcia, Juan Fernando
    Fuentes, David
    Hernandez-Moneo, Jose Luis
    Melendez, Barbara
    NEURO-ONCOLOGY, 2009, 11 (05) : 647 - 647
  • [26] Exportin-1 (XPO1) Inhibition Sequesters p53 from MDM2 and MDM4 and Is Highly Synergistic with MDM2 Inhibition in Inducing Apoptosis in Wild-Type p53 Acute Myeloid Leukemias
    Nishida, Yuki
    Ishizawa, Jo
    Ayoub, Edward
    Montoya, Rafael Heinz
    Ruvolo, Vivian
    Kojima, Kensuke
    Daver, Naval
    Lesegretain, Arnaud
    Shacham, Sharon
    Andreeff, Michael
    BLOOD, 2020, 136
  • [27] CDK4/MDM2 Amplification Is a Rare Targetable Genomic Event in TP53/RB1-Wildtype Uterine Leiomyosarcoma
    Drews-Elger, Katherine
    Pinto, Andre
    Williams, Erik
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1138 - S1139
  • [28] Phase 1/1b Study of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, As Monotherapy or in Combination with Cytarabine for the Treatment of Relapsed/Refractory AML and Advanced MDS with TP53 Wild-Type
    Sallman, David A.
    Borate, Uma
    Cull, Elizabeth H.
    Donnellan, William B.
    Komrokji, Rami S.
    Steidl, Ulrich G.
    Corvez, Maria M.
    Payton, Marie
    Annis, D. Allen
    Pinchasik, Dawn
    Aivado, Manuel
    Verma, Amit
    BLOOD, 2018, 132
  • [29] High amplification levels of MDM2 and CDK4 correlate with poor outcome in patients with dedifferentiated liposarcoma: A cytogenomic microarray analysis of 47 cases
    Ricciotti, Robert W.
    Baraff, Aaron J.
    Jour, George
    Kyriss, McKenna
    Wu, Yu
    Liu, Yuhua
    Li, Shao-Chun
    Hoch, Benjamin
    Liu, Yajuan J.
    CANCER GENETICS, 2017, 218 : 69 - 80
  • [30] Prognostic value of MGMT methylation, TP53 mutation, and MDM2, EGFR, or CDK4 amplification in malignant glioma patients treated with adjuvant temozolomide chemotherapy
    Luyken, C
    Loeser, S
    Blaschke, B
    Köhler, S
    Kreuzmann, A
    Seghrouchni, S
    Reifenberger, G
    Sabel, M
    NEURO-ONCOLOGY, 2005, 7 (03) : 328 - 328
12345